

Appendix to slide44-50: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.
 (First transplants between 1991 and 2024)

Slide44. Survival after Autologous and Allogeneic HCTs				
	Years after the first transplantation	N	OS	95% C.I.
Auto	At transplantation	44,435		
	1 year	34,428	85.2%	84.8 - 85.5%
	5 years	17,424	64.7%	64.2 - 65.2%
	10 years	7,159	53.0%	52.4 - 53.6%
Allo	At transplantation	75,268		
	1 year	46,464	65.9%	65.6 - 66.3%
	5 years	24,990	49.9%	49.5 - 50.3%
	10 years	12,519	45.1%	44.7 - 45.5%

Slide45. Survival after Allogeneic HCTs, by Donor Type and Graft Source				
	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	12,765		
	1 year	9,241	74.3%	73.5 - 75.0%
	5 years	6,210	59.1%	58.2 - 60.0%
	10 years	3,982	55.2%	54.3 - 56.1%
Rel-PB	At transplantation	16,225		
	1 year	9,431	63.0%	62.3 - 63.8%
	5 years	4,124	44.1%	43.3 - 44.9%
	10 years	1,807	38.4%	37.5 - 39.3%
UR-BM	At transplantation	24,653		
	1 year	15,756	67.7%	67.1 - 68.3%
	5 years	9,114	51.8%	51.2 - 52.5%
	10 years	4,576	46.7%	46.1 - 47.4%
UR-PB	At transplantation	2,135		
	1 year	1,301	73.5%	71.5 - 75.4%
	5 years	356	55.2%	52.7 - 57.7%
	10 years	21	47.2%	43.5 - 50.8%
UR-CB	At transplantation	19,490		
	1 year	10,735	59.7%	58.9 - 60.3%
	5 years	5,186	45.1%	44.4 - 45.9%
	10 years	2,133	40.6%	39.8 - 41.4%

Slide46. Survival after HCTs for Leukemia				
	Years after the first transplantation	N	OS	95% C.I.
AML	At transplantation	29,581		
	1 year	17,981	65.1%	64.6 - 65.7%
	5 years	9,126	47.2%	46.6 - 47.8%
	10 years	4,332	42.4%	41.7 - 43.0%
ALL	At transplantation	14,944		
	1 year	10,231	72.6%	71.9 - 73.4%
	5 years	5,568	54.0%	53.1 - 54.8%
	10 years	2,921	49.6%	48.7 - 50.5%
ATL	At transplantation	3,246		
	1 year	1,452	48.1%	46.3 - 49.8%
	5 years	670	32.1%	30.4 - 33.8%
	10 years	287	26.8%	25.0 - 28.5%
CML	At transplantation	4,014		
	1 year	2,778	72.2%	70.8 - 73.6%
	5 years	1,927	60.2%	58.6 - 61.7%
	10 years	1,232	56.0%	54.4 - 57.6%
MDS	At transplantation	8,541		
	1 year	5,228	66.0%	65.0 - 67.0%
	5 years	2,533	48.6%	47.5 - 49.7%
	10 years	1,076	41.6%	40.3 - 42.8%

Slide47. Survival after HCTs for Malignant Lymphoma and MM/PCD				
	Years after the first transplantation	N	OS	95% C.I.
NHL	At transplantation	26,963		
	1 year	17,932	72.6%	72.1 - 73.2%
	5 years	9,590	57.3%	56.6 - 57.9%
	10 years	4,144	49.6%	48.9 - 50.3%
HL	At transplantation	1,963		
	1 year	1,571	87.9%	86.4 - 89.3%
	5 years	851	72.5%	70.2 - 74.6%
	10 years	323	64.2%	61.5 - 66.8%
Other lymphoma / type missing	At transplantation	638		
	1 year	394	71.0%	67.1 - 74.4%
	5 years	204	54.2%	49.8 - 58.4%
	10 years	125	46.1%	41.5 - 50.7%
MM/PCD	At transplantation	15,459		
	1 year	12,665	91.9%	91.4 - 92.3%
	5 years	5,749	67.7%	66.8 - 68.5%
	10 years	1,704	47.0%	45.8 - 48.1%

Slide48. Survival after Autologous HCTs for Acute Leukemia by Recipient Age				
	Years after the first transplantation	N	OS	95% C.I.
AML : Age ≤ 15	At transplantation	237		
	1 year	206	86.9%	81.9 - 90.6%
	5 years	147	64.4%	57.9 - 70.1%
	10 years	111	61.7%	55.1 - 67.6%
AML : Age ≥ 16	At transplantation	1,590		
	1 year	1,255	84.0%	82.1 - 85.8%
	5 years	795	68.6%	66.1 - 70.9%
	10 years	410	65.2%	62.5 - 67.7%
ALL : Age ≤ 15	At transplantation	393		
	1 year	320	81.4%	77.2 - 84.9%
	5 years	230	59.7%	54.6 - 64.3%
	10 years	155	55.4%	50.3 - 60.2%
ALL : Age ≥ 16	At transplantation	351		
	1 year	213	61.6%	56.3 - 66.5%
	5 years	98	31.7%	26.8 - 36.7%
	10 years	55	27.1%	22.3 - 32.1%

Slide49. Survival after Autologous HCTs for Malignant Lymphoma by Recipient Age				
	Years after the first transplantation	N	OS	95% C.I.
NHL : Age ≤ 15	At transplantation	226		
	1 year	176	78.6%	72.7 - 83.5%
	5 years	145	71.4%	65.0 - 76.9%
	10 years	102	70.8%	64.3 - 76.3%
NHL : Age ≥ 16	At transplantation	18,766		
	1 year	13,655	80.3%	79.7 - 80.9%
	5 years	7,108	63.5%	62.7 - 64.2%
	10 years	2,919	54.0%	53.1 - 54.9%
HL : Age ≤ 15	At transplantation	39		
	1 year	34	87.2%	71.9 - 94.5%
	5 years	20	76.2%	59.1 - 86.9%
	10 years	10	76.2%	59.1 - 86.9%
HL : Age ≥ 16	At transplantation	1,741		
	1 year	1,424	90.5%	89.0 - 91.8%
	5 years	774	75.2%	72.9 - 77.4%
	10 years	289	66.8%	63.9 - 69.6%

Slide50. Survival after Autologous HCTs for MM / PCD, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
	At transplantation	14,455		
	1 year	12,109	94.3%	93.9 - 94.7%
	5 years	5,512	70.3%	69.4 - 71.2%
	10 years	1,579	48.5%	47.3 - 49.7%

Appendix to slide51-97: The number of patients in each group and crude survival probabilities at 1, 5 years after transplantation.
(Survival after first HCTs between 2015 and 2024)

Slide51. Survival after Allogeneic HCTs for AML by Donor Type and Graft Source, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	150		
	1 year	111	77.7%	70.1 - 83.6%
	5 years	52	62.4%	53.7 - 69.9%
Rel-PB	At transplantation	104		
	1 year	72	76.1%	66.4 - 83.3%
	5 years	27	54.1%	43.2 - 63.7%
UR-BM	At transplantation	133		
	1 year	100	81.4%	73.5 - 87.1%
	5 years	37	65.8%	56.4 - 73.7%
UR-CB	At transplantation	275		
	1 year	201	84.3%	79.3 - 88.2%
	5 years	67	60.5%	53.4 - 66.8%

Slide52. Survival after Allogeneic HCTs for AML by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	444		
	1 year	313	76.2%	71.9 - 79.9%
	5 years	123	56.4%	51.2 - 61.3%
Rel-PB	At transplantation	3,129		
	1 year	1,901	69.3%	67.6 - 70.9%
	5 years	525	48.3%	46.2 - 50.3%
UR-BM	At transplantation	2,802		
	1 year	1,713	69.4%	67.6 - 71.1%
	5 years	659	51.7%	49.7 - 53.8%
UR-CB	At transplantation	4,610		
	1 year	2,613	63.6%	62.2 - 65.0%
	5 years	864	47.2%	45.6 - 48.8%

Slide53. Survival after HLA-identical Sibling donor HCTs for AML by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	61		
	1 year	56	96.7%	87.3 - 99.2%
	5 years	29	80.0%	66.7 - 88.4%
Advanced risk	At transplantation	28		
	1 year	15	53.6%	33.8 - 69.8%
	5 years	7	42.9%	24.6 - 60.0%

Slide54. Survival after HLA-identical Sibling donor HCTs for AML by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,133		
	1 year	881	85.6%	83.4 - 87.5%
	5 years	304	64.5%	61.2 - 67.6%
Advanced risk	At transplantation	518		
	1 year	242	51.6%	47.1 - 55.8%
	5 years	84	30.8%	26.6 - 35.2%

Slide55. Survival after UR-BMT for AML by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	92		
	1 year	80	93.3%	85.7 - 96.9%
	5 years	31	76.5%	65.5 - 84.4%
Advanced risk	At transplantation	41		
	1 year	20	54.9%	38.3 - 68.8%
	5 years	6	42.0%	25.8 - 57.4%

Slide56. Survival after UR-BMT for AML by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,991		
	1 year	1,394	79.8%	77.9 - 81.5%
	5 years	552	62.0%	59.6 - 64.4%
Advanced risk	At transplantation	806		
	1 year	316	43.8%	40.3 - 47.3%
	5 years	107	27.0%	23.7 - 30.4%

Slide57. Survival after UR-CBT for AML by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	192		
	1 year	160	93.5%	88.9 - 96.3%
	5 years	57	74.3%	66.2 - 80.7%
Advanced risk	At transplantation	83		
	1 year	41	61.9%	49.9 - 71.9%
	5 years	10	28.2%	17.7 - 39.6%

Slide58. Survival after UR-CBT for AML by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	2,402		
	1 year	1,647	77.4%	75.7 - 79.1%
	5 years	555	62.3%	60.1 - 64.4%
Advanced risk	At transplantation	2,207		
	1 year	965	48.6%	46.4 - 50.7%
	5 years	308	31.0%	28.9 - 33.2%

**Slide59. Survival after Allogeneic HCTs for ALL
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	178		
	1 year	149	87.4%	81.6 - 91.6%
	5 years	61	74.2%	66.5 - 80.5%
Rel-PB	At transplantation	101		
	1 year	56	64.2%	53.6 - 73.0%
	5 years	19	44.2%	33.2 - 54.7%
UR-BM	At transplantation	203		
	1 year	164	88.2%	82.8 - 92.0%
	5 years	63	72.2%	64.5 - 78.5%
UR-CB	At transplantation	349		
	1 year	261	87.7%	83.7 - 90.8%
	5 years	116	78.1%	72.8 - 82.5%

**Slide61. Survival after HLA-identical Sibling donor HCTs for ALL
by Disease risk status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	49		
	1 year	43	93.7%	81.8 - 97.9%
	5 years	20	84.2%	69.6 - 92.2%
Advanced risk	At transplantation	60		
	1 year	45	82.6%	70.0 - 90.3%
	5 years	17	65.1%	50.1 - 76.6%

**Slide64. Survival after UR-BMT for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,074		
	1 year	847	86.5%	84.3 - 88.4%
	5 years	356	70.1%	67.0 - 73.1%
Advanced risk	At transplantation	295		
	1 year	173	67.2%	61.3 - 72.4%
	5 years	60	44.2%	37.7 - 50.5%

**Slide60. Survival after Allogeneic HCTs for ALL
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	269		
	1 year	224	88.6%	84.1 - 91.9%
	5 years	99	71.5%	64.9 - 77.0%
Rel-PB	At transplantation	1,234		
	1 year	855	79.8%	77.4 - 82.0%
	5 years	254	61.2%	58.0 - 64.3%
UR-BM	At transplantation	1,369		
	1 year	1,020	82.4%	80.2 - 84.4%
	5 years	416	64.6%	61.7 - 67.4%
UR-CB	At transplantation	1,286		
	1 year	870	76.4%	73.9 - 78.7%
	5 years	298	60.2%	57.1 - 63.1%

**Slide62. Survival after HLA-identical Sibling donor HCTs for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	637		
	1 year	528	91.4%	88.9 - 93.4%
	5 years	222	74.2%	70.1 - 77.8%
Advanced risk	At transplantation	161		
	1 year	106	71.4%	63.6 - 77.8%
	5 years	29	44.0%	35.0 - 52.6%

**Slide65 Survival after UR-CBT for ALL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	150		
	1 year	120	92.9%	87.2 - 96.1%
	5 years	58	84.2%	76.1 - 89.7%
Advanced risk	At transplantation	199		
	1 year	141	83.8%	77.8 - 88.3%
	5 years	58	73.6%	66.1 - 79.6%

**Slide63. Survival after UR-BMT for ALL
by Disease Status, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	96		
	1 year	84	93.5%	86.1 - 97.0%
	5 years	35	83.1%	72.9 - 89.8%
Advanced risk	At transplantation	107		
	1 year	80	83.4%	74.7 - 89.4%
	5 years	28	61.5%	49.6 - 71.3%

**Slide66. Survival after UR-CBT for ALL
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	839		
	1 year	632	85.0%	82.3 - 87.2%
	5 years	242	73.6%	70.2 - 76.8%
Advanced risk	At transplantation	447		
	1 year	238	60.2%	55.4 - 64.7%
	5 years	56	34.4%	29.3 - 39.6%

**Slide67. Survival after Allogeneic HCTs for CML
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	14		
	1 year	11	78.6%	47.3 - 92.5%
	5 years	8	78.6%	47.3 - 92.5%
UR-BM	At transplantation	16		
	1 year	11	81.3%	52.5 - 93.5%
	5 years	6	73.9%	44.2 - 89.4%
UR-CB	At transplantation	6		
	1 year	6	100.0%	
	5 years	4	100.0%	

**Slide68. Survival after Allogeneic HCTs for CML
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	25		
	1 year	23	96.0%	74.8 - 99.4%
	5 years	9	91.8%	71.1 - 97.9%
Rel-PB	At transplantation	194		
	1 year	145	84.9%	78.9 - 89.4%
	5 years	41	66.6%	58.0 - 73.9%
UR-BM	At transplantation	213		
	1 year	155	83.5%	77.6 - 88.0%
	5 years	61	71.2%	63.7 - 77.4%
UR-CB	At transplantation	176		
	1 year	115	76.9%	69.7 - 82.6%
	5 years	50	68.5%	60.2 - 75.4%

**Slide69. Survival after HLA-identical Sibling donor HCTs for CML
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	50		
	1 year	44	100.0%	
	5 years	13	86.6%	67.2 - 94.9%
Advanced risk	At transplantation	66		
	1 year	53	85.9%	74.6 - 92.4%
	5 years	20	66.4%	52.7 - 77.0%

**Slide70. Survival after UR-BMT for CML
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	95		
	1 year	68	84.9%	75.4 - 91.0%
	5 years	22	74.4%	62.7 - 82.9%
Advanced risk	At transplantation	118		
	1 year	87	82.4%	74.1 - 88.3%
	5 years	39	68.9%	58.6 - 77.1%

**Slide71. Survival after UR-CBT for CML
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	66		
	1 year	45	85.8%	74.5 - 92.4%
	5 years	12	81.3%	68.5 - 89.3%
Advanced risk	At transplantation	110		
	1 year	70	71.7%	62.0 - 79.3%
	5 years	38	61.9%	51.3 - 70.9%

**Slide72. Survival after Allogeneic HCTs for MDS
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	58		
	1 year	51	94.8%	84.6 - 98.3%
	5 years	29	90.6%	78.9 - 96.0%
Rel-PB	At transplantation	12		
	1 year	10	90.9%	50.8 - 98.7%
	5 years	4	81.8%	44.7 - 95.1%
UR-BM	At transplantation	116		
	1 year	93	91.0%	83.9 - 95.1%
	5 years	32	76.3%	65.7 - 84.0%
UR-CB	At transplantation	38		
	1 year	29	88.8%	72.7 - 95.6%
	5 years	12	82.4%	64.8 - 91.7%

**Slide73. Survival after Allogeneic HCTs for MDS
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	173		
	1 year	114	70.3%	62.8 - 76.6%
	5 years	45	47.9%	39.7 - 55.7%
Rel-PB	At transplantation	981		
	1 year	569	66.8%	63.7 - 69.8%
	5 years	162	46.7%	43.1 - 50.3%
UR-BM	At transplantation	1,425		
	1 year	879	68.3%	65.8 - 70.7%
	5 years	273	46.8%	43.9 - 49.7%
UR-CB	At transplantation	1,294		
	1 year	707	61.2%	58.5 - 63.9%
	5 years	206	44.7%	41.6 - 47.8%

Slide74. Survival after HLA-identical Sibling donor HCTs for MDS by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	29		
	1 year	26	93.1%	75.1 - 98.2%
	5 years	18	93.1%	75.1 - 98.2%
Advanced risk	At transplantation	6		
	1 year	6	100.0%	
	5 years	4	66.7%	19.5 - 90.4%

Slide77. Survival after UR-BMT for MDS by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	482		
	1 year	319	71.9%	67.6 - 75.8%
	5 years	108	52.1%	47.1 - 57.0%
Advanced risk	At transplantation	891		
	1 year	524	65.9%	62.6 - 69.0%
	5 years	157	43.4%	39.7 - 47.1%

Slide80. Survival after Allogeneic HCTs for NHL by Donor Type and Graft Source, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	24		
	1 year	19	79.2%	57.0 - 90.8%
	5 years	8	75.0%	52.6 - 87.9%
Rel-PB	At transplantation	22		
	1 year	12	58.7%	35.6 - 76.0%
	5 years	5	47.5%	25.1 - 66.9%
UR-BM	At transplantation	31		
	1 year	22	77.3%	58.2 - 88.5%
	5 years	9	68.8%	48.2 - 82.6%
UR-CB	At transplantation	41		
	1 year	29	77.2%	60.7 - 87.4%
	5 years	16	73.5%	56.0 - 84.9%

Slide75. Survival after HLA-identical Sibling donor HCTs for MDS by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	174		
	1 year	122	75.1%	67.8 - 81.0%
	5 years	50	60.3%	52.0 - 67.5%
Advanced risk	At transplantation	304		
	1 year	191	70.2%	64.6 - 75.1%
	5 years	70	48.2%	41.8 - 54.3%

Slide78. Survival after UR-CBT for MDS by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	14		
	1 year	10	84.4%	50.4 - 95.9%
	5 years	5	84.4%	50.4 - 95.9%
Advanced risk	At transplantation	19		
	1 year	14	88.5%	61.4 - 97.0%
	5 years	6	75.9%	47.7 - 90.2%

Slide81. Survival after Allogeneic HCTs for NHL by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	118		
	1 year	68	65.0%	55.5 - 73.0%
	5 years	31	52.7%	42.5 - 61.9%
Rel-PB	At transplantation	1,056		
	1 year	558	57.3%	54.2 - 60.2%
	5 years	160	41.7%	38.4 - 45.0%
UR-BM	At transplantation	592		
	1 year	339	64.0%	59.9 - 67.7%
	5 years	171	50.5%	46.1 - 54.7%
UR-CB	At transplantation	1,136		
	1 year	525	52.0%	49.0 - 55.0%
	5 years	211	40.1%	37.1 - 43.2%

Slide76. Survival after UR-BMT for MDS by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	67		
	1 year	57	95.4%	86.3 - 98.5%
	5 years	26	87.3%	74.8 - 93.9%
Advanced risk	At transplantation	32		
	1 year	24	87.5%	70.0 - 95.1%
	5 years	5	56.3%	30.6 - 75.6%

Slide79. Survival after UR-CBT for MDS by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	387		
	1 year	222	65.2%	60.1 - 69.8%
	5 years	73	49.4%	43.8 - 54.7%
Advanced risk	At transplantation	867		
	1 year	468	59.7%	56.3 - 63.0%
	5 years	130	42.8%	39.0 - 46.5%

Slide82. Survival after HLA-identical Sibling donor HCTs for NHL by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR	At transplantation	159		
	1 year	125	85.7%	79.0 - 90.3%
	5 years	47	67.4%	58.6 - 74.7%
PR	At transplantation	111		
	1 year	78	74.3%	65.0 - 81.5%
	5 years	31	56.5%	46.0 - 65.7%
NIR	At transplantation	223		
	1 year	93	43.7%	37.1 - 50.2%
	5 years	35	31.5%	25.2 - 38.0%

Slide85. Survival after UR-CBT for NHL by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	27		
	1 year	21	84.1%	63.1 - 93.7%
	5 years	11	78.5%	55.3 - 90.6%
NIR	At transplantation	14		
	1 year	8	63.5%	33.1 - 83.0%
	5 years	5	63.5%	33.1 - 83.0%

Slide87. Survival after Autologous HCTs for MM / PCD, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
	At transplantation	8,109		
	1 year	6,564	96.1%	95.6 - 96.5%
	5 years	2,313	79.9%	78.7 - 81.0%

Slide83. Survival after UR-BMT for NHL by Disease Status, Recipient Age ≤15

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	18		
	1 year	12	71.8%	44.9 - 87.2%
	5 years	4	64.6%	37.1 - 82.5%
NIR	At transplantation	13		
	1 year	10	84.6%	51.2 - 95.9%
	5 years	5	76.2%	42.7 - 91.7%

Slide86. Survival after UR-CBT for NHL by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR	At transplantation	328		
	1 year	194	67.8%	62.3 - 72.7%
	5 years	81	57.4%	51.4 - 62.9%
PR	At transplantation	254		
	1 year	125	54.6%	48.1 - 60.7%
	5 years	50	43.7%	37.1 - 50.1%
NIR	At transplantation	553		
	1 year	205	41.6%	37.4 - 45.7%
	5 years	80	28.5%	24.6 - 32.6%

Slide88. Survival after Allogeneic HCTs for MM / PCD by Donor Type and Graft Source, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	88		
	1 year	47	58.6%	47.5 - 68.1%
	5 years	12	34.1%	23.4 - 45.0%
UR-BM	At transplantation	98		
	1 year	56	60.5%	50.0 - 69.5%
	5 years	23	47.4%	36.9 - 57.3%
UR-CB	At transplantation	65		
	1 year	27	43.7%	31.3 - 55.4%
	5 years	4	18.3%	8.8 - 30.7%

Slide84. Survival after UR-BMT for NHL by Disease Status, Recipient Age ≥16

	Years after the first transplantation	N	OS	95% C.I.
CR	At transplantation	268		
	1 year	183	75.3%	69.6 - 80.1%
	5 years	103	59.4%	52.9 - 65.4%
PR	At transplantation	129		
	1 year	74	66.3%	57.2 - 73.9%
	5 years	30	51.5%	41.7 - 60.5%
NIR	At transplantation	195		
	1 year	82	46.7%	39.5 - 53.6%
	5 years	38	37.4%	30.3 - 44.5%

**Slide89. Survival after Autologous HCTs for MM / PCD
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR)	At transplantation	2,067		
	1 year	1,669	97.7%	96.9 - 98.3%
	5 years	527	84.1%	81.8 - 86.1%
VGPR	At transplantation	2,709		
	1 year	2,166	97.1%	96.4 - 97.7%
	5 years	687	80.4%	78.3 - 82.4%
PR	At transplantation	2,361		
	1 year	1,954	95.7%	94.8 - 96.5%
	5 years	791	76.9%	74.7 - 78.9%
SD	At transplantation	163		
	1 year	134	92.8%	87.4 - 95.9%
	5 years	57	68.0%	59.0 - 75.5%
PD / Rel	At transplantation	147		
	1 year	81	66.2%	57.5 - 73.5%
	5 years	22	36.3%	26.9 - 45.7%

**Slide91. Survival after HLA-identical Sibling donor HCTs for MM / PCD
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	35		
	1 year	26	79.7%	62.0 - 89.8%
	5 years	7	45.7%	27.3 - 62.3%
SD / PD / Rel	At transplantation	11		
	1 year	3	27.3%	6.5 - 53.9%
	5 years	0	-	

**Slide94. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	117		
	1 year	104	97.3%	91.8 - 99.1%
	5 years	43	96.4%	90.6 - 98.6%
Rel-PB	At transplantation	9		
	1 year	6	88.9%	43.3 - 98.4%
	5 years	2	88.9%	43.3 - 98.4%
UR-BM	At transplantation	135		
	1 year	113	96.9%	91.9 - 98.8%
	5 years	48	94.2%	88.1 - 97.2%
UR-CB	At transplantation	31		
	1 year	30	100.0%	
	5 years	9	100.0%	

**Slide90. Survival after Allogeneic HCTs for MM / PCD
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	193		
	1 year	117	67.4%	60.2 - 73.7%
	5 years	36	44.6%	36.6 - 52.2%
SD / PD / Rel	At transplantation	73		
	1 year	19	28.5%	18.6 - 39.1%
	5 years	3	11.4%	5.0 - 20.9%

**Slide92. Survival after UR-BMT for MM / PCD
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	71		
	1 year	48	71.2%	58.9 - 80.4%
	5 years	19	58.5%	45.7 - 69.3%
SD / PD / Rel	At transplantation	23		
	1 year	7	34.2%	16.1 - 53.4%
	5 years	3	17.6%	4.8 - 36.9%

**Slide95. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	176		
	1 year	146	92.4%	87.2 - 95.5%
	5 years	61	86.1%	79.3 - 90.8%
Rel-PB	At transplantation	105		
	1 year	81	83.5%	74.9 - 89.4%
	5 years	25	76.4%	65.7 - 84.2%
UR-BM	At transplantation	209		
	1 year	159	83.9%	78.0 - 88.3%
	5 years	81	79.4%	72.8 - 84.5%
UR-CB	At transplantation	114		
	1 year	74	74.3%	65.1 - 81.4%
	5 years	36	69.3%	59.3 - 77.2%

**Slide93. Survival after UR-CBT for MM / PCD
by Disease Status, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	36		
	1 year	20	60.6%	42.7 - 74.5%
	5 years	4	28.7%	13.2 - 46.3%
SD / PD / Rel	At transplantation	29		
	1 year	7	24.1%	10.7 - 40.5%
	5 years	0	-	

**Slide96. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≤15**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	80		
	1 year	71	97.3%	89.6 - 99.3%
	5 years	27	97.3%	89.6 - 99.3%
UR-BM	At transplantation	135		
	1 year	113	96.9%	91.9 - 98.8%
	5 years	48	94.2%	88.1 - 97.2%
UR-CB	At transplantation	31		
	1 year	30	100.0%	
	5 years	9	100.0%	

**Slide97. Survival after Allogeneic HCTs for AA
by Donor Type and Graft Source, Recipient Age ≥16**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	168		
	1 year	141	90.8%	85.2 - 94.4%
	5 years	63	85.4%	78.5 - 90.2%
UR-BM	At transplantation	209		
	1 year	159	83.9%	78.0 - 88.3%
	5 years	81	79.4%	72.8 - 84.5%
UR-CB	At transplantation	114		
	1 year	74	74.3%	65.1 - 81.4%
	5 years	36	69.3%	59.3 - 77.2%